儿童硫嘌呤治疗中6-TGN与6-MMPN核苷酸浓度的相关因素
该研究分析2021年儿童硫嘌呤治疗药物监测首份样本,涵盖急性淋巴细胞白血病和炎症性肠病等适应症,发现仅38.8%患者6-TGN和6-MMPN同时处于推荐范围,年龄、TPMT基因型、硫唑嘌呤剂量及联用药物与6-TGN浓度相关。
要点
- 仅38.8%儿童6-TGN与6-MMPN同时达推荐治疗范围
- ALL中年龄和TPMT基因型与6-TGN升高相关
- IBD中硫唑嘌呤剂量和联用药物影响6-TGN浓度
核心结论
- 治疗药物监测可识别未达标或过度治疗的儿童,有助于调整剂量以减少不良反应并改善疗效。
研究设计与样本
- 回顾性分析2021年收到的首份儿童治疗药物监测样本,共纳入492例患儿,涵盖炎症性肠病、急性淋巴细胞白血病及其他自身免疫病。
主要发现
- 6-TGN中位浓度为213.7 pmol/8×10^8 RBC(四分位距142.5–309.6),6-MMPN中位浓度为1144.6 pmol/8×10^8 RBC(四分位距419.4–3574.3)。
- 38.8%的患者6-TGN和6-MMPN同时处于推荐治疗范围。
- 260例中有57例肝酶或血常规异常,其中8.1%患者丙氨酸氨基转移酶升高,3.4%患者血细胞计数异常。
- 在ALL中,治疗药物监测时年龄和硫嘌呤甲基转移酶基因型与6-TGN升高相关;在IBD中,硫唑嘌呤剂量与6-TGN升高相关,且IBD患者联用药物影响显著。
关键数值与推荐
- 6-TGN目标浓度范围为200–500 pmol/8×10^8 RBC,6-MMPN目标浓度范围为<6000 pmol/8×10^8 RBC。
临床怎么用
- 临床可依据年龄、硫嘌呤甲基转移酶基因型、硫唑嘌呤剂量及联用药物解读6-TGN和6-MMPN浓度,识别未达标或过度治疗患儿并调整剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Azathioprine (AZA) and 6-mercaptopurine are prescribed in acute lymphoblastic leukaemia (ALL) and inflammatory bowel diseases (IBD). Metabolism to active 6-thioguanine (6TGN) and 6-methylmercaptopurine nucleotides (6MMPN) is variable but therapeutic drug monitoring (TDM) remains debatable. This study reports on factors impacting on red blood cell (RBC) metabolites concentrations in children to facilitate TDM interpretation. METHODS: The first paediatric TDM samples received during year 2021 were analysed, whatever indication and thiopurine drug. Target concentration ranges were 200-500, <6000 pmol/8 × 108 RBC for 6TGN and 6MMPN. RESULTS: Children (n = 492) had IBD (64.8%), ALL (22.6%) or another autoimmune disease (12.6%): mean ages at TDM were 7.5 in ALL and 13.7 years in IBD (P < .0001). ALL received 6-mercaptopurine (mean dose 1.7 mg/kg/d with methotrexate), IBD received AZA (1.9 mg/kg/d with anti-inflammatory drugs and/or monoclonal antibodies). Median 6TGN and 6MMPN concentrations were 213.7 [interquartile range: 142.5; 309.6] and 1144.6 [419.4; 3574.3] pmol/8 × 108 RBC, 38.8% of patients were in the recommended therapeutic range for both compounds. Aminotransferases and blood tests were abnormal in 57/260 patients: 8.1% patients had high alanine aminotransaminase, 3.4% of patients had abnormal blood count. Factors associated with increased 6TGN were age at TDM and thiopurine methyltransferase genotype in ALL and AZA dose in IBD. The impact of associated treatment in IBD patients was also significant. CONCLUSION: TDM allowed identification of children who do not reach target levels or remain over treated. Including TDM in follow-up may help physicians to adjust dosage with the aim of reducing adverse effects and improve treatment outcome.
引用
- de Beaumais TA, Lorrain S, Mamhoudi N, et al. Key factors associated with 6-thioguanine and 6-methylmercaptopurine nucleotide concentrations in children treated by thiopurine for acute leukaemia and inflammatory bowel disease. Br J Clin Pharmacol. 2023. PMID: 37621013. doi:10.1111/bcp.15894
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。